Investigating nerve growth factor changes as a sign of early Alzheimer's disease
Nerve growth factor (NGF) metabolic dysfunction as a marker of cognitive decline in autosomal dominant Alzheimer's disease
This study is looking at how changes in a protein related to nerve growth might help us spot early signs of Alzheimer's disease in people who have a genetic risk for it, so we can find ways to help them before symptoms start.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10447866 on NIH RePORTER |
What this research studies
This research focuses on understanding how changes in nerve growth factor (NGF) metabolism can indicate the early stages of Alzheimer's disease (AD) before clinical symptoms appear. By analyzing biofluids like plasma and cerebrospinal fluid from individuals with genetic mutations linked to familial AD, the study aims to identify reliable biomarkers that signal the onset of cognitive decline. The approach involves comparing NGF pathway proteins in carriers of the presenilin1 gene mutation with those who do not carry the mutation, providing insights into the disease's progression. This could lead to earlier interventions for those at risk of developing AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with familial mutations associated with Alzheimer's disease, particularly those carrying the presenilin1 gene mutation.
Not a fit: Patients with sporadic Alzheimer's disease or those without any familial history of the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enable earlier detection and intervention for individuals at risk of Alzheimer's disease, potentially slowing or preventing cognitive decline.
How similar studies have performed: Previous research has shown promise in using biomarkers for early detection of Alzheimer's disease, suggesting that this approach could be a meaningful advancement in the field.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Quiroz, Yakeel T. — Massachusetts General Hospital
- Study coordinator: Quiroz, Yakeel T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.